| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Vantictumab | OMP-18R5; anti-Fzd7 | Phase 1 Clinical | Oncomed Pharmaceuticals Inc, Bayer AG | Solid tumours; Pancreatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |




